Articles
 News Headlines
 Journal Headlines

  Home
  Archives
  Site Map
   
September 23, 2014
 
About AIDScience
Contact Us
——
NeuroAIDS
 
 
 
 

News Article Headline
 

VaxGen's AIDS vaccine for developing world shows unexpected activity

Source: VaxGen, Inc

BRISBANE, Calif., June 26 -- VaxGen, Inc. (Nasdaq: VXGN) presented laboratory data today at an international scientific conference indicating that antibodies to HIV subtype C (HIV-C) have an unexpected ability to bind to significant regions of another HIV subtype. The findings indicate that a vaccine that induces HIV-C antibodies may be effective at preventing infection not only by HIV-C but by other subtypes as well. HIV-C causes half of the world''''s HIV infections and is the predominant subtype in southern Africa, India and China. VaxGen also described a new trivalent formulation of its vaccine, AIDSVAX, which is designed to prevent infection by three of the world''''s five major HIV subtypes, including HIV-C. The development of this formulation, which has yet to be tested in human clinical trials, furthers the company''''s goal of tailoring vaccines to target specific HIV subtypes and strains in various geographic regions.
—Posted: June 26, 2001

More news headlines: This week | Last week | Search archive

                                                                                                                                                                                                                                                                                                                             


 

 

 
Privacy Policy     Site Map    
 
Published by the American Association for the Advancement of Science.
 

 
Copyright © 2003 by the American Association for the Advancement of Science.